- Home
- DLY vs CRMD Comparison
DLY vs CRMD Comparison
Compare DLY & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLY
- CRMD
- Stock Information
- Founded
- DLY 2019
- CRMD 2006
- Country
- DLY United States
- CRMD United States
- Employees
- DLY N/A
- CRMD N/A
- Industry
- DLY Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- DLY Finance
- CRMD Health Care
- Exchange
- DLY Nasdaq
- CRMD Nasdaq
- Market Cap
- DLY 759.6M
- CRMD 877.5M
- IPO Year
- DLY N/A
- CRMD 2010
- Fundamental
- Price
- DLY $15.37
- CRMD $11.28
- Analyst Decision
- DLY
- CRMD Strong Buy
- Analyst Count
- DLY 0
- CRMD 7
- Target Price
- DLY N/A
- CRMD $17.33
- AVG Volume (30 Days)
- DLY 215.9K
- CRMD 2.2M
- Earning Date
- DLY 01-01-0001
- CRMD 08-13-2025
- Dividend Yield
- DLY 8.93%
- CRMD N/A
- EPS Growth
- DLY N/A
- CRMD N/A
- EPS
- DLY N/A
- CRMD 0.28
- Revenue
- DLY N/A
- CRMD $82,553,827.00
- Revenue This Year
- DLY N/A
- CRMD $238.38
- Revenue Next Year
- DLY N/A
- CRMD $53.52
- P/E Ratio
- DLY N/A
- CRMD $40.46
- Revenue Growth
- DLY N/A
- CRMD N/A
- 52 Week Low
- DLY $13.26
- CRMD $3.61
- 52 Week High
- DLY $15.95
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- DLY 37.61
- CRMD 39.54
- Support Level
- DLY $15.45
- CRMD $11.13
- Resistance Level
- DLY $15.59
- CRMD $11.86
- Average True Range (ATR)
- DLY 0.10
- CRMD 0.65
- MACD
- DLY -0.02
- CRMD -0.34
- Stochastic Oscillator
- DLY 12.50
- CRMD 3.81
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.